Mirvetuximab Soravtansine for Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
J. Clin. Oncol 2023 Jan 30;[EPub Ahead of Print], UA Matulonis, D Lorusso, A Oaknin, S Pignata, A Dean, H Denys, N Colombo, T Van Gorp, JA Konner, MR Marin, P Harter, CG Murphy, J Wang, E Noble, B Esteves, M Method, RL ColemanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.